EU Clinical Trials Regulation (EU) No 536/2014 - Clinical Trials Regulation

What it says

Clinical trials conducted in the EU must be authorized and conducted under a harmonized framework covering trial approval, safety reporting and investigational medicinal product manufacturing and labeling, with investigational products required to be manufactured in accordance with GMP principles specific to investigational products.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• This Regulation's manufacturing obligations for investigational medicinal products connect directly to EU GMP Annex 13, which supplies the detailed GMP expectations specific to investigational products referenced at a framework level here.
• Because investigational products are, by definition, not yet fully characterized the way an approved commercial product is, labeling, blinding and randomization controls carry particular weight in demonstrating that patients receive the correct, properly controlled product.
• The harmonized single-submission approach this Regulation introduced for multi-country trials means manufacturing and quality documentation often needs to satisfy reviewers across several member states simultaneously, not just one national authority.

What inspectors look for

• Whether investigational medicinal product manufacturing and labeling controls meet the GMP expectations referenced for investigational products, including blinding and randomization integrity.
• Whether batch documentation for investigational products provides the same traceability and accountability expected of commercial product manufacturing, adapted to the trial's specific design.
• Whether changes to the investigational product during the course of a trial were assessed and documented consistently with the trial's authorized manufacturing information.

Related regulations